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Abstract
Thrombotic thrombocytopenic purpura (TTP) is a type of thrombotic microangiopathy (TMA). Studies report that the
majority of TTP patients present with a deficiency of ADAMTS13 activity. In a database of TMA patients in Japan identified
between 1998 and 2008, 186 patients with first onset of acquired idiopathic (ai) ADAMTS13-deficient TTP (ADAMTS13
activity ,5%) were diagnosed. The median age of onset of TTP in this group of patients was 54 years, 54.8% were female,
75.8% had renal involvement, 79.0% had neurologic symptoms, and 97.8% had detectable inhibitors to ADAMTS13 activity.
Younger patients were less likely to present with renal or neurologic dysfunction (p,0.01), while older patients were more
likely to die during the TTP hospitalization (p,0.05). Findings from this cohort in Japan differ from those reported
previously from the United States, Europe, and Korea with respect to age at onset (two decades younger in the other
cohort) and gender composition (60% to 100% female in the other cohort). We conclude that in one of the largest cohorts
of ai-TTP with severe deficiency of ADAMTS13 activity reported to date, demographic characteristics differ in Japanese
patients relative to those reported from a large Caucasian registry from Western societies. Additional studies exploring these
findings are needed.
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Introduction
Thrombotic thrombocytopenic purpura (TTP) is a life-threat-
ening generalized disorder and originally defined by classic
‘‘pentad’’; thrombocytopenia, microangiopthic hemolytic anemia
(MAHA), renal impairment, neurological symptoms, and fever [1].
In 1998, two studies identified deficiency of plasma ADAMTS13
(a disintegrin-like and metalloprotease with thrombospndin type 1
motifs 13) activity (ADAMTS13:AC) among persons with TTP
[2,3]. ADAMTS13 cleaves the peptide bond between Thy1605
and Met1606 in the A2 domain of von Willebrand factor (VWF)
subunit. VWF is synthesized in vascular endothelial cells and
megakaryocytes. Vascular endothelial cell-derived VWF is re-
leased into the plasma as unusually large VWF multimers (UL-
VWFMs). UL-VWFMs are degraded into smaller size VWF
multimers by ADAMTS13. Severe deficiency of ADAMTS13:AC,
either congenital or acquired, results in accumulation of UL-
VWFMs and formation of platelet thrombi in the microvascula-
tures. In congenital TTP (Upshaw-Schulman syndrome),
ADAMTS13 deficiency is caused by mutations in the
ADAMTS13 gene [4]. In contrast, acquired TTP is frequently
caused by inhibitory autoantibodies against ADAMTS13 [2,3].
Most acquired TTP patients have IgG antibodies. In rare cases,
IgA and/or IgM antibodies are associated with IgG antibodies
[5,6]. Patients with severe ADAMTS13:AC deficiency present
with a lower platelet count and a significantly increased risk of
TTP relapse [7–10]. Only a few small cohort studies of acquired
idiopathic TTP patients characterized by severe ADAMTS13:AC
deficiency have been reported previously. These studies charac-
terize TTP with a predilection for the young and female, high
rates of renal and central nervous system (CNS) involvement, and
a 15% to 20% mortality. The largest cohort of acquired idiopathic
(ai)-severely ADAMTS13-deficient TTP patients previously re-
ported is from the Oklahoma TTP Registry (n=60) [10]. In this
study we systematically analyzed the clinical and laboratory
features of a large cohort of Japanese patients with acquired
idiopathic TTP and who also have severe ADAMTS13:AC
deficiency.
Results
The number of ai-TTP patients fit the above inclusion criteria
and retained for the study was 186. Of these, 31 (16.7%) were
diagnosed between 1998 and 2001, 84 (45.2%) between 2002 and
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did not experience any exposure to drugs that cause TTP or
TMA, organ transplantation, stem cell transplantation, immuno-
logic disease and also did not have a prior history of TTP. The age
distribution of disease onset ranged from 8 months to 87 years old,
with peak incidence occurring at age 60 (Figure 1, upper panel).
Patients under 20 years accounted for 9.1% (17/186) of this
subgroup, while patients over age 80 years accounted for 3.8% (7/
186). Females accounted for 54.8%. Laboratory studies revealed
that 100% of these patients were thrombocytopenic, 75.8% had
renal involvement, and 79.0% had neurologic involvement.
Overall, 16.1% died from TTP. ADAMTS13 inhibitors
($0.5 BU/ml) were identified in 182 patients (97.8%). As shown
in Figure 1 lower panel, 8.1% of these patients had inhibitor titers
of 0.5,,1.0 BU/ml, 35.5% had titers of 1.0,,2.0, 33.3% had
inhibitor titers of 2.0,,5.0, 12.9% had inhibitor titers of
5.0,,10, and 8.1% had inhibitor titers of $10 BU/ml. We
found four ai-TTP patients without ADAMTS13 inhibitor
(,0.5 BU/ml), whose ADAMTS13:AC, however, was normalized
after remission. Therefore, these patients were included in this
study.
The ai-TTP patients were evaluated according to the age at
diagnosis (Table 1); Group 1 (,20 years old: n=17), Group 2
(20,,40 years old: n=36), Group 3 (40,,60 years old: n=63),
and Group 4 (60 years old,: n=70). Rates of renal and
neurologic dysfunction at the time of TTP presentation were
lowest in the youngest age-subgroup (52.9% versus 72.2% to
81.0% for renal involvement, and 47.0% versus 69.4% to 88.6%
for neurologic involvement; p,0.01) while in-patient mortality
was highest among the oldest sub-group (28.6% versus 5.9% to
11.1%, p,0.01). Overall, females accounted for 54.8% of the
patients (with rates of female gender ranging from 45.7% to 69.4%
in each of the four age-groups).
Discussion
We evaluated 186 patients with initial onset of severely deficient
ADAMTS13:AC levels TTP in Japan, representing the largest
cohort of ai-TTP patients with ADAMTS13:AC deficiency
reported from Japan. These individuals had presented with
TMA-findings to medical centers throughout Japan over a ten-
year period. In interpreting our findings, several factors should be
considered.
These individuals accounted for 71.5% of 260 patients with a
first episode of ai-TTP, who were diagnosed in out registry. This
rate is similar to that reported previously for smaller cohorts of
TTP patients from Europe, the United States, Canada, the United
Kingdom, and Korea [7–13].
Sociodemographic characteristics of these TTP patients were
compared to those reported from cohorts in Oklahoma, Saint
Louis, France, and Korea [7–10,13] (Table 2). The median age of
TTP patients with severely deficient ADAMTS13:AC levels
reported from the other cohorts except for Saint Louis is 15 to
20 years less than that reported for our cohort. Also, females
accounted for 53.8% of patients in our cohort versus 60% to 100%
in other cohorts. Since additional information on predisposing
factors for TTP are not known currently, it is not possible to
identify factors accounting for age- and gender-related differences
noted between TTP patients in Japan with severe ADAMTS13-
deficiency versus those reported from other geographic regions.
Age-related differences in rates of neurologic and renal
involvement among TTP patients who had severely deficient
ADAMTS13:AC levels have not been reported previously. We
found lower rates of renal and neurologic dysfunction amongst the
youngest TTP patients, and the highest short-term mortality rates
among the oldest TTP patients. While our study evaluated 186
patients with initial onset of severe ADAMTS13:AC activity
Figure 1. Age distribution and ADAMTS13 inhibitor levels in acquired idiopathic (ai2) TTP with severe deficiency of ADAMTS13
activity. Upper panel shows the age distribution of 186 patients with severe deficiency of ADAMTS13 activity under 5%. We found wide range of the
age at TTP bouts from 8 months old to 87 years old. The highest incident peak was found around 60 years old. Lower panel shows the distribution of
ADAMTS13 inhibitors in 186 ai-TTP patients with severe deficiency of ADAMTS13 activity. We found ADAMTS13 inhibitors ($0.5 BU/ml) in 182
patients (97.8%). High titer inhibitors $2.0 BU/ml was seen in 101 patients (54.3%).
doi:10.1371/journal.pone.0033029.g001
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All patients Groups according to age
1 234O v e r a l l p
Age (years) 54 (37, 65) ,20 20,,40 40,,60 60,
Median (25, 75
percentile)
Patient Number 186 17 36 63 70
Female (%) 54.8 52.9 69.4 57.1 45.7 NS
‘‘Pentad’’
(1) Platelet count (610
9/L), Median (25, 75 percentile) 10 (7, 16) 9 (7, 12) 10 (7, 20) 10 (6, 18) 10 (8, 15) NS
(2) Hemoglobin (g/dL), Median (25, 75 pecentile) 7.3 (6.1, 8.7) 7.4 (5.4, 8.7) 6.7 (5.9, 7.8) 7.1 (6.0, 8.8) 7.8 (6.6, 8.8) NS
(3) Renal involvement (%) 75.8 52.9 72.2 81.0 78.5 NS
Serum creatinine (mg/dL), Median (25, 75 percntile) 0.9 (0.7, 1.3) 0.58 (0.31, 0.80) 0.86 (0.70, 1.16) 0.95 (0.80, 1.50) 1.00 (0.80, 1.40) ,0.01
a
Blood urea nitrogen (mg/dL), Median (25, 75 percntile) 24 (17, 37) 15 (12, 23) 19 (14, 26) 27 (17, 41) 27 (21, 43) ,0.01
b
(4) CNS involvement (%) 79.0 47.0 69.4 82.5 88.6 ,0.01
c
(5) Fever ($37.0uC) (%) 71.5 76.5 63.9 69.8 75.7 NS
Mortality in the current episode of TTP bouts (%) 16.1 5.9 5.6 11.1 28.6 ,0.05
d
NS: not significant difference ($0.05).
Overall p values were caluculated using the Kruskal-Wallis H tests or chi-square tests with Yates’ correction for 264 tables.
Significant differnces between 4 groups (overall p,0.05) were further analyzed by Mann-Whitney U-test or chi-squre test.
ap,0.01 between Group 1 and Groups 2, 3, 4.
bp,0.01 between Group 1 and Groups 3, 4, and between Group 2 and Groups 3, 4.
cp,0.01 between Group 1 and Groups 3, 4.
dp,0.05 between Group 2 and Group 4.
doi:10.1371/journal.pone.0033029.t001
Table 2. Comparison of our findings with those reported from Europe, Asia, and the United States for acquired idiopathic TTP
patients with severely deficient ADAMTS13:AC levels.
This study Vesely et al
7 Zheng et al
8 Coppo et al
9 Kremer-Hovinga et al
10 Jang et al
13
(n=180) (n=16) (n=16) (n=31) (n=60) (n=20)
Geographic region Japan Oklahoma (USA) Saint Louis (USA) France Oklahoma (USA) Korea
Ethnicity/race Japanese 100% White 50%, White 32%, White 52%, African-American 35% Korean 100%
African-American 50% African-American 68% Afro-Caribbean 48%
Idiopathic etiology 100% 100% 100% 100% 77% 70%
Prior TMA 0% 0% 38% 13% 0% ND
ADAMTS13:AC ,5% ,5% ,5% ,5% ,10% ,10%
ADAMTS13:INH 98% 94% 44% 55% 83% ND
Age (years) 54 (8 m–87) 39 (19–71) 51 (21–79) 36 (19–67) 41 (9–72) 40.5 (mean)
% female 55 75 100 65 82 60
Platelets (10
9/ul) 10 (1–88) 11(4–27) 17 (6–47) 12 (2–69) 11 (2–101) 24 (mean)
Hb (g/dl) 7.3 (4.3–11.9) ND ND 7.3 (4.6–13.7) ND 7.7 (mean)
Ht (%) ND 21 (15–30) 25 (13–33) ND 21 (13–33) ND
Creatinine (mg/dl) 0.9 (0.7–10.7) 1.2(0.9–5.5) 1.1 (0.7–3.1) 1.1 (0.67–5.2) 1.6 (0.7–6.6) 1.6 (mean)
BUN (mg/dl) 23.4 (2.5–154) ND ND ND ND ND
Fever (%) 72 ND 31 36 ND 70
CNS involvement (%) 79 50 56 74 50 25
% Survival 84 81 81 87 78 81
ND: no data.
Median (minimum-maximum).
doi:10.1371/journal.pone.0033029.t002
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with idiopathic TTP and severe ADAMTS13:AC deficiency [7–
9,11–13]. These age-related differences in clinical findings may
account in part for higher short-term mortality rates observed
among older patients with TTP in our cohort, as well as in the
cohort reported from Canada [14].
Fourth, inhibitory autoantibodies against ADAMTS13 were
identified in 97.8% of patients with ADAMTS13:AC deficient
TTP. Other cohorts identify inhibitory antibodies in 44% to 94%
of TTP patients with severely deficient ADAMTS13:AC levels [7–
13]. These findings reflect variable sensitivity and specificity of
ADAMTS13:AC inhibitor tests. In our study, ADAMTS13
inhibitor levels of 5 or more BU/ml were identified in 21.0% of
TTP patients with severely deficient ADAMTS13:AC levels and
inhibitor levels of 10 or more BU/ml were noted in 8.1%. These
TTP patients with severely deficient ADAMTS13:AC activity
levels and high titer inhibitors to ADAMTS13 might represent a
subgroup of TTP patients for whom rituximab therapy might be
particularly beneficial [12]. In general, the role of IgG antibody
levels in ai-TTP is felt to be controversial. Some investigators
report an association of higher titers with increased mortality,
refractoriness, and more severe presentation [10,15], while others
have not found similar results [7,16].
Our study has the limitation that follow-up ended at the time of
hospital discharge, which prevented us from reporting on relapse
rates and long-term survival rates. A second limitation is that TTP
patients who were not severely deficient in ADAMTS13:AC levels
were not included in this study. As noted by others, this is a
heterogenous group of patients- many of whom have diseases
other than TTP. Another limitation is that while our laboratory is
a distinguished referral center for TMAs in Japan, it is not
mandatory that information on all TMA patients is sent to our
laboratory, and hence a number of patients with TMAs in Japan
are not entered into our database. A final limitation is that cohorts
in two of the five comparison studies (from Korea and Oklahoma)
included a minority of individuals with TTP who did not have
primary idiopathic TTP [10,13].
In summary, findings from this cohort of TTP patients in Japan
with severe ADAMTS13:AC deficiency parallel those reported
from TTP cohorts in Europe, the United States, Canada, the
United Kingdom, and Korea in several ways, but also provide
insights that have not been reported previously [7–14]. Novel
findings in this cohort include females accounting for only 54.8%
of incident cases, a higher median age at TTP onset of 54 years,
and higher mortality rates amongst patients who were older than
60 years of age. Given the rarity of TTP in the general population,
aggregation of findings from various TTP cohorts reported from
Japan, Korea, France, England, Saint Louis, Oklahoma, and
Canada might yield important findings that single registries would
be unable to identify. A particularly important finding might be
development and validation of a multivariate model predictive of
mortality of persons with incident TTP characterized by severe
ADAMTS13:AC deficiency.
Methods
Since 1998, our laboratory has been a nationwide referral center
within Japan for TMAs, with 919 patients having been registered in
this database [17]. During the first years of the study, samples from
all TMA patients were evaluated by our referral center. In recent
years, commercial laboratories now provide access to ADAMT-
S13:AC evaluation and some centers therefore do not submit
samplesto ourgroup.We arenotable toascertainwhichcentersare
sending samples to commercial vendors at this time. Of these 919
patients, 186 patients were diagnosed with first onset of ai-TTP
characterized by severe deficiency of ADAMTS13:AC (,5%) and
no prior history of TTP. Exclusion criteria were exposure to drugs
that cause TTP or TMA, organ transplantation, stem cell
transplantation, immunologic disease, or ADAMTS13:AC levels
5% and more. All patients gave written informed consent to
participate in this study. The study protocol was approved by the
Ethics Committee of Nara Medical University Hospital.
Diagnostic criteria
The classic pentad for TTP was defined as follows (i)
microangiopathic hemolytic anemia (hemoglobin #12 g/dL),
Coombs test negative, undetectable serum haptoglobin
(,10 mg/dL), more than 2 fragmented red cells (schistocytes) in
a microscopic field with a magnification of 100, and concurrent
increased serum lactate dehydrogenase (LDH) above institutional
baseline, (ii) thrombocytopenia (platelet count #100610
9/L), (iii)
fever $37uC, (iv) CNS involvement: ranging from headache to
coma, including neurological dysfunction, convulsion, clouding of
consciousness, and (v) renal involvement (including abnormal
urinalysis in addition to elevation of serum creatinine level).
Patients were excluded if they reported a prior episode of ai-
severely ADAMTS13-deficient TTP (n=18 patients).
Blood Sampling
Before therapeutic approaches were initiated, whole blood
samples (,5 ml) were phlebotomized from each patient and
placed into plastic tubes containing 1/10 volume of 3.8% sodium
citrate. The plasma was separated by centrifugation at 3000 g for
15 min at 4uC, kept in aliquots at 280uC until testing, and sent to
our laboratory with clinical information.
Assays of plasma ADAMTS13:AC and ADAMTS13:INH
Until March 2005, ADAMTS13:AC was determined by classic
von Willebrand factor multimer (VWFM) assay with a detection
limit of 3% of the normal control [18,19]. Thereafter, a
chromogenic ADAMTS13-act-ELISA [20] with a detection limit
of 0.5% of the normal control was developed, and replaced the
VWFM assay. Thus, most of the plasma samples stored at 280uC
were re-evaluated with chromogenic act-ELISA, but 22 samples
were unable to evaluate by the new method, because of a short of
the stored sample volume. Basically, however, the results obtained
by both the assays had a high correlation (r=0.99) [20]. Thus, the
results determined by VWFM alone were also included in this
study. Further, to compare the results from other investigators and
potentially with different assay methods for ADAMTS13:AC, we
here categorized plasma levels of ADAMTS13:AC of severe
(,5%), moderate (5%,,25%), mild (25%,,50%) deficiency
and normal ($50%) of ADAMTS13:AC. Plasma ADAMT-
S13:INH titers were analyzed either by classic VWFM assay or
chromogenic ADAMTS13-act-ELISA using heat-inactivated plas-
mas at 56uC for 30 min. Briefly, the tested samples were mixed
with an equal volume of the normal plasmas and incubated at
37uC for 2 hours. After incubation, the residual ADAMTS13:AC
was measured. One Bethesda unit (BU) is defined as the amount
necessary to reduce ADAMTS13:AC to 50% of control levels
according to the Bethesda method, which was originally developed
for the measurement of factor VIII inhibitor [21]. Titers
$0.5 BU/ml were classified as inhibitor-positive.
Statistical analysis
All continuous variables were reported as median values (25, 75
percentile). Comparisons between two patient groups (severe
Acquired Idiopathic ADAMTS13 Deficient TTP
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statistical significance using the Mann-Whitney U-tests or chi-
square tests. Comparisons between 4 patients groups (under 20
years old, 20 to under 40 years old, 40 to under 60 years old, and
over 60 years old) were calculated using the Kruskal-Wallis H tests
or chi-square tests with Yates’ correction for 264 tables.
Significant differences between 4 groups (overall p,0.05) were
further analyzed by Mann-Whitney U-tests or chi-square tests.
Correlation between ADAMTS13:AC and :INH was analyzed by
Sperman’s correlation. A two-tailed P value less than 0.05 was
considered to be significant.
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